Zobrazeno 1 - 10
of 13
pro vyhledávání: ''
Autor:
Pavel Jindra, Riita Niittyvuopio, Hervé Tilly, Jakob Passweg, Gesine Bug, Dietrich W. Beelen, Klaus Hirschbühl, Bruno Lioure, Mohamad Mohty, Arnon Nagler, Jan J. Cornelissen, Sebastian Giebel, Hélène Labussière-Wallet, Myriam Labopin, Mohamed Houhou, C. Schmid, Gerald Wulf, Ludovic Gabellier
Publikováno v:
Bone Marrow Transplantation, 56(5), 1190-1199. Nature Publishing Group
Second- and third-generation tyrosine kinase inhibitors (TKI) play an important role in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). However, data on feasibility and efficacy of using these drugs for pers
Autor:
Dietrich W. Beelen, Arnon Nagler, Riitta Niittyvuopio, Yngvar Fløisand, Mahmoud Aljurf, Jurjen Versluis, Frédéric Baron, Zinaida Peric, Ali Bazarbachi, Charles Craddock, Fabio Ciceri, Anne Huynh, Francesco Lanza, Arnold Ganser, Maria H. Gilleece, Annalisa Ruggeri, Gesine Bug, Eolia Brissot, Norbert Claude Gorin, Mohamad Mohty, Uwe Platzbecker, Jan J. Cornelissen, Myriam Labopin, Florent Malard, J. Sanz, Sebastian Giebel, Didier Blaise, Roni Shouval, Laimonas Griskevicius, Gérard Socié, Jordi Esteve, Noel Milpied, Bipin N. Savani, Christoph Schmid, Alexandros Spyridonidis
Publikováno v:
Bone Marrow Transplantation, 55(6), 1114-1125. Nature Publishing Group
BONE MARROW TRANSPLANTATION
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
BONE MARROW TRANSPLANTATION
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
To address limitations of the currently used reduced-intensity/myeloablative conditioning (RIC/MAC) classification scheme we aimed to develop a tool that can capture more standardized the conditioning intensity of allogeneic hematopoietic cell transp
Autor:
Paolo Corradini, Gerald Wulf, Christopher P. Fox, Lutz P. Müller, Nicolaus Kröger, Nadira Duraković, Michel van Gelder, Nicolaas Schaap, Jan J. Cornelissen, Peter Dreger, Mohamad Sobh, Christof Scheid, Hélène Schoemans, Paul Browne, Linda Koster, Jennifer Hoek, Mauricette Michallet, Silvia Montoto, William Krüger, Ariane Boumendil, Wolfgang Bethge, Jakob Passweg, Johannes Schetelig, Domenico Russo
Publikováno v:
Bone Marrow Transplantation, 55, 884-890
Bone Marrow Transplantation, 55(5), 884-890. Nature Publishing Group
Bone Marrow Transplantation, 55, 5, pp. 884-890
Bone Marrow Transplantation, 55(5), 884-890. Nature Publishing Group
Bone Marrow Transplantation, 55, 5, pp. 884-890
Contains fulltext : 220662.pdf (Publisher’s version ) (Closed access) The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%
Autor:
Bondanza, A., Ruggeri, L., Noviello, M., Eikema, D.J., Bonini, C., Chabannon, C., Werf, S. van der, Biezen, A. van, Wreede, L.C. de, Crucitti, L., Vago, L., Merluzzi, M., Massei, M.S., Veelken, H., Koc, Y., Bader, P., Gruhn, B., Locatelli, F., Ciceri, F., Toubert, A., Velardi, A., Bernardo, M.E., Dazzi, F., Ellard, R., Fleischhauer, K., Greco, R., Hudecek, M., Kohl, U., Kuball, J., Malard, F., Pedrazzoli, P., Rocha, V., Ruggeri, A., Urbano-Ispizua, A., Wang, J.F., Wieten, L., EBMT Cell Therapy Immunobiol Worki
Publikováno v:
Bone Marrow Transplantation, 54(6), 867-876. Nature Publishing Group
Bone Marrow Transplantation, 54(6), 867-876
Bone Marrow Transplantation, 54(6), 867-876
HLA-haploidentical haematopoietic stem cell transplantation (haplo-HSCT) is increasingly offered to patients with high-risk acute leukaemia. Unfortunately, haplo-HSCT is followed by a delayed immunoreconstitution. The aim of this EBMT registry study
Autor:
Gloria Tridello, Didier Blaise, Patrice Chevallier, Grzegorz W. Basak, Eric Deconinck, Jan Styczyński, Nicolaus Kröger, Diana Averbuch, Ibrahim Yakoub-Agha, Silvia Montoto, Nicolaas Schaap, Edouard Forcade, Rafael de la Cámara, Nina Knelange, Stephanie Nguyen-Quoc, Jakob Passweg, Catherine Cordonnier, Lidia Gil, Jan J. Cornelissen, Mauricette Michallet, Simone Cesaro, Katherine N. Ward, Nigel H. Russell, Gérard Socié, Eefke Petersen, Per Ljungman, Hendrik Veelken, Nathalie Fegueux, Peter Bader, Malgorzata Mikulska, Johan Maertens
Publikováno v:
Bone Marrow Transplantation, 54(12), 2060-2071. Nature Publishing Group
Bone Marrow Transplantation, 54(12), 2060-2071. NATURE PUBLISHING GROUP
Bone Marrow Transplantation, 54, 12, pp. 2060-2071
Bone Marrow Transplantation, 54, 2060-2071
Bone Marrow Transplantation, 54(12), 2060-2071. NATURE PUBLISHING GROUP
Bone Marrow Transplantation, 54, 12, pp. 2060-2071
Bone Marrow Transplantation, 54, 2060-2071
The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients
Autor:
Hayashi, H., Ruggeri, A., Volt, F., Cornelissen, J.J., Socie, G., Sengeloev, H., Michallet, M., Karakasis, D., Petersen, E., Cahn, J.Y., Veelken, H., Mercier, M., Rohrlich, P.S., Rafii, H., Kenzey, C., Xavier, E., Duarte, R.F., Basak, G.W., Rocha, V., Gluckman, E., Eurocord Complications Quality
Publikováno v:
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Bone Marrow Transplantation, 53(4), 417-421
Bone Marrow Transplantation, 53(4), 417-421. Nature Publishing Group
Universidade de São Paulo (USP)
instacron:USP
Bone Marrow Transplantation, 53(4), 417-421
Bone Marrow Transplantation, 53(4), 417-421. Nature Publishing Group
Autor:
Neil Cambronero, K Kowalek, Christopher C. Dvorak, B D Barrows, P C Ursell, Matt S. Zinter, Katrina Kalantar, Joseph L. DeRisi, Peter Oishi
Publikováno v:
Bone Marrow Transplantation
Bone marrow transplantation, vol 52, iss 9
Zinter, MS; Barrows, BD; Ursell, PC; Kowalek, K; Kalantar, K; Cambronero, N; et al.(2017). Extracorporeal life support survival in a pediatric hematopoietic cellular transplant recipient with presumed GvHD-related fulminant myocarditis. BONE MARROW TRANSPLANTATION, 52(9), 1330-1333. doi: 10.1038/bmt.2017.114. UCSF: Retrieved from: http://www.escholarship.org/uc/item/8qq44499
Bone marrow transplantation, vol 52, iss 9
Zinter, MS; Barrows, BD; Ursell, PC; Kowalek, K; Kalantar, K; Cambronero, N; et al.(2017). Extracorporeal life support survival in a pediatric hematopoietic cellular transplant recipient with presumed GvHD-related fulminant myocarditis. BONE MARROW TRANSPLANTATION, 52(9), 1330-1333. doi: 10.1038/bmt.2017.114. UCSF: Retrieved from: http://www.escholarship.org/uc/item/8qq44499
Extracorporeal life support survival in a pediatric hematopoietic cellular transplant recipient with presumed GvHD-related fulminant myocarditis
Autor:
Jan Zuna, Eva Fronkova, Jan Stary, J. Trka, Monika Brüggemann, J. J. M. Van Dongen, Petr Sedlacek, V H J van der Velden, Michaela Kotrova, Renata Formankova
Publikováno v:
Bone Marrow Transplantation, 52(7), 962-968. Nature Publishing Group
Bone Marrow Transplantation, 52(7), 962-968
Bone Marrow Transplantation, 52(7), 962-968
Minimal residual disease (MRD) monitoring via quantitative PCR (qPCR) detection of Ag receptor gene rearrangements has been the most sensitive method for predicting prognosis and making post-transplant treatment decisions for patients with ALL. Despi
Autor:
Simone Cesaro, Chiara Bonini, Carlo Dufour, Peter Dreger, Jakob Passweg, Anna Sureda, D Farge-Bancel, Peter Bader, Arnon Nagler, Francesco Lanza, Kröger N, Andrew R. Gennery, Jürgen Kuball, Mohamad Mohty, Helen Baldomero, R. F. Duarte
Publikováno v:
Bone Marrow Transplantation
Europe PubMed Central
Bone Marrow Transplantation, 51, 786–792. Nature Publishing Group
Europe PubMed Central
Bone Marrow Transplantation, 51, 786–792. Nature Publishing Group
A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. Trends include: continued growth in transp
Autor:
Adetola A. Kassim, Robert F. Cornell
Publikováno v:
Bone Marrow Transplantation
The use of modern therapies such as thalidomide, bortezomib and lenalidomide coupled with upfront high-dose therapy and autologous stem cell transplant (ASCT) has resulted in improved survival in patients with newly diagnosed multiple myeloma (MM). H